Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity The research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands Boehringer Ingelheim’s research into approaches with first in…
Gubra is awarded EY Entrepreneur of the Year 2020, Region Zealand for the 2nd year in a row. The digital award ceremony took place 3rd December. The jury highlights “…the strong and passionate entrepreneur who is behind this year’s regional…
HØRSHOLM, Denmark – May 26, 2020 Gubra sets a new standard for simple and comparable CSR reporting. In the company’s first CSR Report for 2019, Gubra proves that it is possible to design a short and informative CSR report that…
Hørsholm, Denmark 15 May 2020 In 2019 Gubra maintains strong financial growth based on solid results in both the biotech business and the CRO business. Gross profit increases 40% to 149M DKK in 2019. Pre-tax profits increase by 70% to…
HØRSHOLM, Denmark – March 9, 2020 Gubra is sponsor of this year’s Danish bike campaign BIKE TO WORK BIKE TO WORK (VI CYKLER TIL ARBEJDE) is Denmark’s big national bike event. Due to corona-virus/COVID-19 this year’s bike event is moved…
HØRSHOLM, Denmark – March 6, 2020 Congratulations to Gubra and PhD student Mathias Bonde Møllerhøj (MSc). We just received a co-financed industrial PhD scholarship from the Danish Diabetes Academy for Mathias’ research project “Identification and validation of fibrosis targets in…
HØRSHOLM, Denmark – October 30, 2019 Tuesday evening at Ledreborg Castle took a sweeping turn upwards for Jacob Jelsing and Niels Vrang when they proudly stepped up at the podium to receive this year’s title and prize as EY Entrepreneur of the…
HØRSHOLM, Denmark – June 28, 2019 On September 7, 2017, Boehringer Ingelheim and Gubra announced a collaboration for the development of novel peptide compounds to treat obesity. In June 2019, the first clinical candidate from this collaboration was nominated, which…
INGELHEIM, Germany and HØRSHOLM, Denmark – May 29, 2019 Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available. New collaboration aims to develop novel peptide poly-agonists for the treatment…
New York and Hørsholm, Denmark, 18 June 2018 JDRF and Gubra today announced a partnership to develop a glucose-responsive insulin (GRI) as a treatment for people with insulin-requiring diabetes, such as type 1 diabetes (T1D). The Gubra approach is based…